Sign in Sign up for free

Last updated: 4 June 2024 at 4:42pm EST

Daniel Tasse Net Worth




The estimated Net Worth of Daniel Tasse is at least $533 Thousand dollars as of 8 March 2024. Mr. Tasse owns over 17,094 units of Regenxbio Inc stock worth over $217,265 and over the last 10 years he sold RGNX stock worth over $0. In addition, he makes $315,316 as Independent Director at Regenxbio Inc.

Mr. Tasse RGNX stock SEC Form 4 insiders trading

Daniel has made over 2 trades of the Regenxbio Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 17,094 units of RGNX stock worth $14,188 on 8 March 2024.

The largest trade he's ever made was buying 25,000 units of Regenxbio Inc stock on 19 February 2015 worth over $300,000. On average, Daniel trades about 1,830 units every 144 days since 2015. As of 8 March 2024 he still owns at least 17,094 units of Regenxbio Inc stock.

You can see the complete history of Mr. Tasse stock trades at the bottom of the page.





Daniel Tasse biography

Daniel Tasse serves as Independent Director of the Company. He has been a Director since August 2016. Mr. Tassé has served as the Chief Executive Officer of DBV Technologies SA, a publicly held biopharmaceutical company, since November 2018. From March 2016 to March 2019, he was the Chairman of Alcresta Therapeutics, Inc. (“Alcresta”), a privately held biopharmaceutical company, and from March 2016 to November 2018, he was the Chairman and Chief Executive Officer of Alcresta. Mr. Tassé has served as a director at Indivior PLC (where he is the Lead Independent Director), a London Stock Exchange publicly traded pharmaceutical company, since August 2014. Additionally, he has served as a director at Bellerophon Therapeutics, Inc. (“Bellerophon”), a publicly held biopharmaceutical company, since December 2013, HLS Therapeutics Inc. (“HLS”), a Toronto Stock Exchange publicly traded pharmaceutical company, since March 2018, and BioQ Pharma (“BioQ”), a privately held pharmaceutical company, since December 2014, but Mr. Tasse does not expect to stand for re-election at Bellerophon, HLS or BioQ in 2019. Prior to the acquisition of Ikaria Inc. (“Ikaria”) by Mallinckrodt Pharmaceuticals in April 2015, Mr. Tassé was President, Chief Executive Officer and Chairman of Ikaria and served as the Interim Chief Executive Officer and President of Bellerophon from February 2014 to June 2014. Previously, Mr. Tassé was the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. and Vice President and Regional Director for Australasia at GlaxoSmithKline plc. Mr. Tassé was a member of the Health Section Governing Board of the Biotechnology Industry Organization, where he participated on the bioethics, regulatory environment and reimbursement committees. Additionally, Mr. Tassé was a member of the board of directors of the Pharmaceutical Research and Manufacturers of America, where he participated on the FDA and biomedical research committee.

What is the salary of Daniel Tasse?

As the Independent Director of Regenxbio Inc, the total compensation of Daniel Tasse at Regenxbio Inc is $315,316. There are 16 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.



How old is Daniel Tasse?

Daniel Tasse is 60, he's been the Independent Director of Regenxbio Inc since 2016. There are 9 older and 10 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.

What's Daniel Tasse's mailing address?

Daniel's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Regenxbio Inc

Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.



What does Regenxbio Inc do?

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.



What does Regenxbio Inc's logo look like?

Regenxbio Inc logo

Complete history of Mr. Tasse stock trades at Bellerophon Therapeutics Inc, DBV Technologies, and Regenxbio Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
8 Mar 2024 DBVT DBV Technologies Daniel Tasse
CHIEF EXECUTIVE OFFICER
 Buy 17,094 $0.83 $14,188
8 Mar 2024
17,094 ↗
19 Feb 2015 BLPH Bellerophon Therapeutics Inc Daniel Tasse
Director
 Buy 25,000 $12.00 $300,000
19 Feb 2015
128,898 ↗


Regenxbio Inc executives and stock owners

Regenxbio Inc executives and other stock owners filed with the SEC include: